ANDA 202047, held by Pharmazone. Rizatriptan Benzoate.
As of Nov 14, 2026, ANDA 202047 (Rizatriptan Benzoate), held by Pharmazone, was first approved by FDA on Dec 31, 2012, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 31, 2012 | Original application | Approved | None posted |
| Rizatriptan BenzoateEQ 5MG BASE · tablet;oral | Rizatriptan Benzoate | Rx |
| Rizatriptan BenzoateEQ 10MG BASE · tablet;oral | Rizatriptan Benzoate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
